Literature DB >> 11130776

Obesity-hypertension: the effects on cardiovascular and renal systems.

R Zhang1, E Reisin.   

Abstract

Longitudinal and cross-sectional studies suggest that a large number of obese patients have a high prevalence of hypertension. This association causes the following changes: insulin and leptin resistance with a suppressed biologic activity of natriuretic peptide, which contributes to sodium retention with concomitant expanded cardiopulmonary volume and increased cardiac output. The cellular metabolism of cations may be altered in obesity and may lead to changes in vascular responsiveness and increased vascular resistance. These changes lead to structural adaptations in the heart characterized by concentric-eccentric left ventricular hypertrophy. The hypertrophic condition provides the basis for the development of congestive heart failure and cardiac arrhythmias that may explain the higher rates of cardiac sudden death in those patients. In the kidneys, obesity hypertension may initiate a derangement of renal function. The increased deposit of interstitial cells and of extracellular matrix between the tubules induces higher interstitial hydrostatic pressure and tubular sodium reabsorption. The consequent increase in renal flow and glomerular filtration enhances albuminuria excretion and the susceptibility to the development of renal damage. In summary, the hemodynamic and structural adaptations related to obesity hypertension is the cause of greater risk for adverse cardiovascular and renal events.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11130776     DOI: 10.1016/s0895-7061(00)01254-1

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  24 in total

Review 1.  Regression of left ventricular hypertrophy is a key goal of hypertension management.

Authors:  Rubin Zhang; Judy Crump; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

2.  [Modification of heart failure risk by obesity. Selected aspects of the Framingham Study].

Authors:  W A Scherbaum
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

3.  Strong association of physical job demands with functional limitations among active people: a population-based study in North-eastern France.

Authors:  N Chau; M Khlat
Journal:  Int Arch Occup Environ Health       Date:  2009-02-18       Impact factor: 3.015

Review 4.  The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches.

Authors:  Zohreh Soltani; Vaughn Washco; Stephen Morse; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

Review 5.  Healthy weight - healthy blood pressure.

Authors:  Arun Chockalingam
Journal:  Can J Cardiol       Date:  2010-05       Impact factor: 5.223

Review 6.  The pathophysiology of hypertension in patients with obesity.

Authors:  Vincent G DeMarco; Annayya R Aroor; James R Sowers
Journal:  Nat Rev Endocrinol       Date:  2014-04-15       Impact factor: 43.330

Review 7.  Cardiovascular disease in diabetes and the cardiometabolic syndrome: focus on minority women.

Authors:  John Nicasio; Fadi El-Atat; Samy I McFarlane; Judith H LaRosa
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

8.  Thrombospondin 1 mediates renal dysfunction in a mouse model of high-fat diet-induced obesity.

Authors:  Wenpeng Cui; Hasiyeti Maimaitiyiming; Xinyu Qi; Heather Norman; Shuxia Wang
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-17

9.  Prevalence and determinants of isolated systolic hypertension among young adults: the 1999-2004 US National Health And Nutrition Examination Survey.

Authors:  Regina C Grebla; Carlos J Rodriguez; Luisa N Borrell; Thomas G Pickering
Journal:  J Hypertens       Date:  2010-01       Impact factor: 4.844

Review 10.  Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management.

Authors:  Fadi El-Atat; Samy I McFarlane; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.